Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2023 | Targeting the complement cascade in autoimmune hemolytic anemias

Catherine Broome • 18 Dec 2023

ASH 2023

Autoimmune Hemolytic Anemia Cold Agglutinin Disease Non-Malignant

Catherine Broome, MD, Georgetown University Hospital, Washington, DC, discusses the promise of targeting the complement cascade in warm and cold autoimmune hemolytic anemias (AIHAs). An FDA-approved treatment already exists for patients with cold agglutinin disease (CAD), targeting the classical complement pathway, which is responsible for the hemolysis observed in these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria: Sanofi, Alexion, Argenx, Apellis, Dianthus Therapeutics.

Unmet needs in the treatment and management of cold agglutinin disease

Catherine Broome • 18 Dec 2023

Sutimlimab in cold agglutinin disease: a post-hoc analysis of safety data from CARDINAL & CADENZA

Catherine Broome • 18 Dec 2023

Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP

Catherine Broome • 18 Dec 2023

Evaluating the suitability of sHLH diagnostic criteria in adults

Catherine Broome • 12 Dec 2022

Related Videos

The MDT in the new era of gene therapy for hemoglobinopathies

Mattia Algeri • 15 Apr 2024

Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases

Rita Beier • 15 Apr 2024

A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs

Ali Taher • 15 Apr 2024

The future of CAR T-reg cells: organ transplantation & autoimmune disease

Zinaida Good • 9 Apr 2024